Researchers: HtrA1 Augmentation is Potential Therapy for AMD

Learn More

Beyond the Eye Chart: Scientists Identify Reading Ability and Speed as Crucial Measures of AMD Visual Decline

Learn More
AMD treatment

SCTM: Turning Genetic Discoveries into Treatments for Age-Related Macular Degeneration

Learn More
UREAD image

Utah Retinal Reading Center: 'Grading' the Language of the Eye

Learn More

New Perspectives on Age-Related Macular Degeneration

Learn More

Be Undaunted: A Look Back by Gregory S. Hageman, PhD

Learn More

Sharon Eccles Steele Center for Translational Medicine (SCTM)

The Sharon Eccles Steele Center for Translational Medicine (SCTM) was founded in 2009 to effectively turn scientific discoveries into clinical diagnostic tools and therapies for patients suffering from blinding diseases.

The SCTM is primarily focused on developing treatments for age-related macular degeneration (AMD), a leading cause of vision impairment among adults age 55 and over. AMD affects more than 20 million individuals in the United States, and its prevalence is projected to double by 2050. AMD causes a gradual loss of vision that results in significantly reduced quality of life and often depression. Progression to the late stage of AMD often leads to irreversible vision loss. No therapies currently exist to prevent or slow the progression of AMD.

The SCTM is at the forefront of AMD research and has profoundly changed how drugs against this disease are developed. With the support of committed donors, SCTM Executive Director Gregory S. Hageman, PhD, and his team have turned a series of groundbreaking discoveries into scientifically sound strategies to prevent the onset of all forms of AMD or to slow their progression, with great benefit for patients and their families.

From left, SCTM Executive Director Gregory S. Hageman, PhD; Sharon Eccles Steele; and Moran CEO Randall J Olson, MD.